BASF inorganic specialties divestiture creates new business named Callery
Current product portfolio includes a range of specialty alkoxide bases and borane derivatives.
BASF has created Callery as the new stand-alone entity born from BASF's divestment of its inorganic specialties business. The divestiture was facilitated by Edgewater Capital in combination with the Callery management team. Callery is a global leader in highly reactive chemistries, supplying products to the pharmaceutical, fine, and specialty chemical arenas.
Callery's current product portfolio includes a range of specialty alkoxide bases and borane derivatives, as well as a variety of custom products based on the company's core competency in the handling of highly reactive compounds. Callery's world-class facility includes R&D labs, pilot plant, large-scale production facilities and all knowledge associated with existing and developmental products.
Bob Girton, member of Callery's Board of Directors, said: "We are grateful for all of the hard work by the transition team over the last several months for helping us carve out the Callery business from BASF with minimal impact on our customers. We are excited to join them in taking Callery to its next level of success and build on the business' commitment to environmental health and safety, a high level of product quality, and industry leading reagent and organometallic technology."
The company's products have enabled some of the world's most impressive innovations, including billion-dollar blockbuster drugs, agro chemicals, and other high performance products from electronics to polymer applications.
Soon, Callery will be announcing its new management team to lead the company on its growth path in the coming years. The company is committed to the continued delivery of innovative products that enable customer success.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.